Elinzanetant was associated with significant reductions in vasomotor symptoms and a favorable safety profile at 1 year among menopausal women.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback